CD8A and glioblastoma: In GBM specifically, Lathia and colleagues observed that treatment with Ibudilast, which is a brain-penetrant MIF-CD74 interaction inhibitor (an axis that MDSCs rely heavily upon), reduced the functionality of MDSCs and enhanced the activity of CD8 T cells in the GBM microenvironment [70].